

Bibliografia **Dott. Nicola Nicolai**

Date: 1.2015 Indexed citations only

H-Index:14

- 1) **Nicolai N**, Necchi A, Raggi D, BIASONI D, Catanzaro M, Piva L, Stagni S, Maffezzini M, Torelli T, Faré E, Giannatempo P, Pizzocaro G, Colecchia M, Salvioni R. Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. *Urology*. 2015 Feb;85(2):402-6. doi: 10.1016/j.urology.2014.10.021
- 2) Necchi A, Mariani L, Di Nicola M, Lo Vullo S, **Nicolai N**, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, BIASONI D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment for patients with poor prognosis germ cell tumors: mature results of an Italian randomized phase II study. *Ann Oncol*. 2014 Oct 24. pii: mdu485.
- 3) Giannatempo P, Greco T, Mariani L, **Nicolai N**, Tana S, Farè E, Raggi D, Piva L, Catanzaro M, BIASONI D, Torelli T, Stagni S, Avuzzi B, Maffezzini M, Landoni G, De Braud F, Gianni AM, Sonpavde G, Salvioni R, Necchi A. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. *Ann Oncol*. 2014 Sep 11. pii: mdu447.
- 4) Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, Raggi D, **Nicolai N**, Piva L, Catanzaro M, BIASONI D, Torelli T, Stagni S, Maffezzini M, Gianni AM, De Braud F, Mariani L, Sonpavde G, Colecchia M, Salvioni R. Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. *Clin Genitourin Cancer*. 2014 Aug 8. pii: S1558-7673(14)00174-8. doi: 10.1016/j.clgc.2014.08.002.
- 5) Raggi D, Giannatempo P, Miceli R, Farè E, Piva L, BIASONI D, Catanzaro M, Torelli T, Stagni S, Marongiu M, Gianni AM, **Nicolai N**, Salvioni R, Necchi A. Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. *Am J Clin Oncol*. 2014 Aug 7. [Epub ahead of print] PMID:25089532
- 6) Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, Marongiu M, Scanagatta P, Duranti L, Giovannetti R, Girelli L, **Nicolai N**, Piva L, BIASONI D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Gianni AM, Mariani L, Pastorino U, Salvioni R. A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. *Clin Genitourin Cancer*. 2014 Jun 24. pii: S1558-7673(14)00125-6. doi: 10.1016/j.clgc.2014.06.014. [Epub ahead of print] PMID: 25044148
- 7) Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, **Nicolai N**, Piva L, BIASONI D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Mariani L, Salvioni R. Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy

and Implications for Trial Design. *Clin Genitourin Cancer*. 2014 Jun 11. pii: S1558-7673(14)00104-9. doi: 10.1016/j.clgc.2014.06.003. [Epub ahead of print] PMID: 25027186

- 8) Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, **Nicolai** N, Serafini G, Padovano B, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Mariani L, Gianni AM, Sonpavde G, Salvioni R, Necchi A, Crippa F. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. *Clin Genitourin Cancer*. 2014 Dec;12(6):433-9. doi: 10.1016/j.clgc.2014.03.007. Epub 2014 Mar 28. PMID: 24787972
- 9) Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, **Nicolai** N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor ? (TGF?) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. *Invest New Drugs*. 2014 Jun;32(3):555-60.
- 10) Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrone K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, **Nicolai** N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrone U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol*. 2014 Sep;66(3):489-99.
- 11) Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, **Nicolai** N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. *Clin Genitourin Cancer*. 2014 Jun;12(3):203-209
- 12) Torelli T, Lughezzani G, Catanzaro M, **Nicolai** N, Colecchia M, Biasoni D, Piva L, Maffezzini M, Stagni S, Necchi A, Giannatempo P, Farè E, Salvioni R. Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. *Tumori*. 2013 Sep-Oct;99(5):e203-7. doi: 10.1700/1377
- 13) Necchi A, Miceli R, Pedrazzoli P, Giannatempo P, Secondino S, Di Nicola M, Farè E, Raggi D, Magni M, Matteucci P, Longoni P, Milanese M, Paternò E, Ravagnani F, Arienti F, **Nicolai** N, Salvioni R, Carlo-Stella C, Gianni AM. Predictors of CD34+ cell mobilization

and collection in adult men with germ cell tumors: implications for the salvage treatment strategy. *Clin Genitourin Cancer*. 2014 Jun;12(3):196-202.e1

- 14) Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Crestani A, Guttilla A, Raggi D, Giannatempo P, Necchi A, Pizzocaro G, Colecchia M, Salvioni R, **Nicolai N**. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. *J Urol*. 2014 Apr;191(4):977-82.
- 15) Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, **Nicolai N**, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. *Br J Cancer*. 2014 Jan 7;110(1):26-33.
- 16) Necchi A, **Nicolai N**, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. *Clin Genitourin Cancer*. 2014 Feb;12(1):63-69.e1.
- 17) Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Necchi A, Giannatempo P, Raggi D, Fare E, Colecchia M, Pizzocaro G, Salvioni R, **Nicolai N**. The Relationship Between Lymph Node Ratio and Cancer-Specific Survival in a Contemporary Series of Patients with Penile Cancer and Lymph Node Metastases. *BJU Int*. 2013 Oct 15. doi: 10.1111/bju.12510. [Epub ahead of print] PMID:24128128
- 18) Necchi A, **Nicolai N**, Mariani L, Raggi D, Farè E, Giannatempo P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Milani A, Piva L, Pizzocaro G, Gianni AM, Salvioni R. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. *Ann Oncol*. 2013 Nov;24(11):2887-92.
- 19) Giannatempo P, Paolini B, Miceli R, Raggi D, **Nicolai N**, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. *J Urol*. 2013 Nov;190(5):1919-24.
- 20) Bellardita L, Rancati T, Alvisi MF, Villani D, Magnani T, Marengi C, **Nicolai N**, Procopio G, Villa S, Salvioni R, Valdagni R. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. *Eur Urol*. 2013 Jul;64(1):30-6.
- 21) Procopio G, Verzoni E, Testa I, **Nicolai N**, Salvioni R, Debraud F. Experience with sorafenib in the treatment of advanced renal cell carcinoma. *Ther Adv Urol*. 2012 Dec;4(6):303-13

- 22) **Nicolai N.** Has dynamic sentinel node biopsy achieved its top performance in penile cancer? What clinicians still need to manage lymph nodes in early stage penile cancer. *Eur Urol.* 2013 Apr;63(4):664-6.
- 23) Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, **Nicolai N**, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol.* 2013 Apr;24(4):878-88.
- 24) Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, **Nicolai N**, De Braud F, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. *Lancet Oncol.* 2012 Aug;13(8):810-6.
- 25) Magnani T, Valdagni R, Salvioni R, Villa S, Bellardita L, Donegani S, **Nicolai N**, Procopio G, Bedini N, Rancati T, Zaffaroni N. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. *BJU Int.* 2012 Oct;110(7):998-1003
- 26) Salvioni R, **Nicolai N**, Necchi A, Torelli T, Piva L, Stagni S, Catanzaro MA, Biononi D, Milani A, Colecchia M, Spreafico C, Morosi C, Marchianò A, Crippa F The treatment of early-stage germ cell tumors of the testis (GCTT). *Urologia.* 2012 Apr-Jun;79(2):81-8.
- 27) Trama A, Mallone S, **Nicolai N**, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer.* 2012 Jan;48(2):159-69.
- 28) Spreafico C, **Nicolai N**, Lanocita R, Morosi C, Catanzaro M, Civelli E, Torelli T, Stagni S, Piva L, Frigerio LF, Marchianò A, Salvioni R. CT-guided percutaneous cryoablation of renal masses in selected patients. *Radiol Med.* 2012 Jun;117(4):593-605.
- 29) **Nicolai N**, Colecchia M, Biononi D, Catanzaro M, Stagni S, Torelli T, Necchi A, Piva L, Milani A, Salvioni R. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage I nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection. *J Urol.* 2011 Oct;186(4):1298-302.

- 30) Necchi A, **Nicolai** N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. *J Clin Oncol*. 2011 Aug 1;29(22):e650-2.
- 31) Pizzocaro G, Schiavo M, Solima S, Vitellaro M, BIASONI N, **Nicolai** N. Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003. *Urologia*. 2010 Oct-Dec;77 Suppl 17:50-6.
- 32) Colecchia M, Necchi A, Paolini B, **Nicolai** N, Salvioni R. Teratoma with somatic-type malignant components in germ cell tumors of the testis: a clinicopathologic analysis of 40 cases with outcome correlation. *Int J Surg Pathol*. 2011 Jun;19(3):321-7.
- 33) Salvioni R, **Nicolai** N, Necchi A, Torelli T, Piva L, Stagni S, Catanzaro MA, BIASONI D, Milani A, Rosselliniss I.. State of the art and controversies in the treatment of testis germ-cell tumors (TGT). *Urologia*. 2009 October-December;76(4):221-229.
- 34) Procopio G, Guadalupi V, Giganti MO, Mariani L, Salvioni R, **Nicolai** N, Capone F, Valdagni R, Bajetta E. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. *BJU Int*. 2011 Jul;108(2):223-7.
- 35) International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. *J Clin Oncol*. 2010 Nov 20;28(33):4906-11.
- 36) **Nicolai** N, Necchi A, Piva L, Stagni S, Catanzaro MA, BIASONI D, Milani A, Torelli T, Salvioni R. Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND). *Urologia*. 2010 Apr-May;77(2):84-7
- 37) Necchi A, Colecchia M, **Nicolai** N, Piva L, Catanzaro M, BIASONI D, Torelli T, Stagni S, Paolini B, Milani A, Salvioni R. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. *BJU Int*. 2011 Apr;107(7):1088-94.
- 38) Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrone K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, **Nicolai** N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeny L; IMPACT Study Collaborators, Easton DF, Eeles RA. Targeted prostate cancer screening in men with

mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU Int.* 2011 Jan;107(1):28-39.

- 39) Colecchia M, Necchi A, Paolini B, **Nicolai N**, Salvioni R. Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation. *Int J Surg Pathol.* 2010 Dec 6. [Epub ahead of print]
- 40) Salvioni R, **Nicolai N**, Necchi A, Torelli T, Piva L, Stagni S, Catanzaro MA, Biasoni D, Milani A, Rosselliniss I. State of the art and controversies in the treatment of testis germ-cell tumors (TGT). *Urologia.* 2009 October-December;76(4):221-229.
- 41) Procopio G, Guadalupi V, Giganti MO, Mariani L, Salvioni R, **Nicolai N**, Capone F, Valdagni R, Bajetta E. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. *BJU Int.* 2010 Nov 15. doi: 10.1111/j.1464-410X.2010.09825.x. [Epub ahead of print]
- 42) International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. *J Clin Oncol.* 2010 Nov 20;28(33):4906-11. Epub 2010 Oct 18
- 43) **Nicolai N**, Necchi A, Piva L, Stagni S, Catanzaro MA, Biasoni D, Milani A, Torelli T, Salvioni R. Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND). *Urologia.* 2010 Sep 28;77(2):84-87.
- 44) Necchi A, Colecchia M, **Nicolai N**, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Paolini B, Milani A, Salvioni R. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. *BJU Int.* 2010 Sep 24. doi: 10.1111/j.1464-410X.2010.09705.x. [Epub ahead of print]
- 45) **Nicolai N**, Miceli R. Reply to Ilker Akyol, Hasan Soydan, and Ferhat Ates' Letter to the Editor re: Nicola Nicolai, Rosalba Miceli, Andrea Necchi, et al. Retroperitoneal Lymph Node Dissection With No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. *Eur Urol* 2010;58:912–8 *Eur Urology*, Volume 59, Issue 4, April 2011, Pages e21–e22
- 46) Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, **Nicolai N**, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeny L; IMPACT Study Collaborators, Easton DF, Eeles RA. Targeted prostate cancer screening in men with

- mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU Int.* 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14.
- 47) **Nicolai N**, Miceli R, Necchi A, Biasoni D, Catanzaro M, Milani A, Piva L, Pizzocaro G, Stagni S, Torelli T, Salvioni R. Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. *Eur Urol.* 2010 Dec;58(6):912-8.
- 48) Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines Working Group. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010 May;21 Suppl 5:v147-54. No abstract available.
- 49) Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines Working Group. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010 May;21 Suppl 5:v140-6. No abstract available.
- 50) Puppo P, Conti G, Francesca F, Mandressi A, Naselli A; AURO.it guideline committee. New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. *BJU Int.* 2010 Jul;106(2):168-79. Epub 2010 Mar 23. Review.
- 51) Salvioni R, Necchi A, Piva L, Colecchia M, **Nicolai N**. Penile cancer. *Urol Oncol.* 2009 Nov-Dec;27(6):677-85.
- 52) Necchi A, **Nicolai N**, Salvioni R. Re: Roisin M. Connolly, John A. McCaffrey. High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review. *Eur Urol* 2009;56:57-64. *Eur Urol.* 2010 Jan;57(1):e5-6. Epub 2009 Oct 4. No abstract available.
- 53) Colecchia M, **Nicolai N**, Secchi P, Bandieramonte G, Paganoni AM, Sangalli LM, Pizzocaro G, Piva L, Salvioni R. pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy. *Anal Quant Cytol Histol.* 2009 Jun;31(3):153-60.
- 54) Mattavelli F, Collini P, Pizzi N, **Nicolai N**, Pennacchioli E; Thyroid Study Group. Thyroid as a target of metastases: a case of metastatic seminoma in a patient who died of a second cancer. *Tumori.* 2009 Jan-Feb;95(1):91-3.
- 55) Necchi A, **Nicolai N**, Colecchia M, Salvioni R. Understanding the somatic-type malignant differentiation in male germ-cell cancer: a work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: a chemoresistant phenotype. *Urol Oncol* 2008;26:595-9. *Urol Oncol.* 2009 Mar-Apr;27(2):218; author reply 218-9.
- 56) **Nicolai N**, Necchi A, Gianni L, Piva L, Biasoni D, Torelli T, Stagni S, Milani A, Pizzocaro G, Salvioni R. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. *BJU Int.* 2009 Aug;104(3):340-6. Epub 2009 Feb 23.

- 57) Pizzocaro G, **Nicolai N**. Rebuttal from Authors re: Oliver W. Hakenberg. A New Neoadjuvant Chemotherapy Regimen for Penile Cancer with Nodal Metastases: A Step Forward. *Eur Urol*. In press. doi:10.1016/j.eururo.2008.11.043. *Eur Urol*. 2008 Dec 12.
- 58) Pizzocaro G, **Nicolai N**, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. *Eur Urol*. 2009 Mar;55(3):546-51.
- 59) Necchi A, **Nicolai N**, Salvioni R Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?: Reply to the article "A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors" by C. Theodore et al. (*Ann Oncol* 2008; doi: 10.1093/annonc/mdn122). *Ann Oncol*. 2008 Aug;19(8):1509. Epub 2008 May 25.
- 60) Necchi A, **Nicolai N**, Salvioni R. Testis tumors: what is new?. *Urologia*. 2008 April-June;75(1):63-66.
- 61) De Giorgi U, **Nicolai N**, Tana S, Tavolini IM, Palazzi S, Bracarda S, Tedeschi L, Palmieri G, Frassinetti L, Da Pozzo L, Pastorino U, Emiliani E, Marangolo M, Pizzocaro G, Rosti G, Salvioni R; Italian Germ cell cancer Group. IGG practice guidelines on germ cell tumor in adult male patients. *Tumori*. 2008 Jan-Feb;94(1):96-109.
- 62) Bandieramonte G, Colecchia M, Mariani L, Lo Vullo S, Pizzocaro G, Piva L, **Nicolai N**, Salvioni R, Lezzi V, Stefanon B, De Palo G. Penoscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. *Eur Urol*. 2008 Oct;54(4):875-82. Epub 2008 Jan 15.
- 63) Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, **Nicolai N**, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Potttek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. *Eur Urol*. 2008 Mar;53(3):478-96. Epub 2007 Dec 26.
- 64) Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, **Nicolai N**, Oliver T, Ondrus D, Oosterhof

- GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. *Eur Urol.* 2008 Mar;53(3):497-513. Epub 2007 Dec 26.
- 65) Doherty R, Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, Bancroft E, Mitra A, Morgan S, Eeles R; IMPACT steering committee and collaborators. Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions. *Hered Cancer Clin Pract.* 2007 Mar 15;5(1):53-5.
- 66) Colecchia M, Nistal M, Gonzalez-Peramato P, Carmignani L, Salvioni R, **Nicolai N**, Regadera J. Leydig cell tumor and hyperplasia: a review. *Anal Quant Cytol Histol.* 2007 Jun;29(3):139-47.
- 67) **Nicolai N**, Piva L, Pizzocaro G, Salvioni R. Re: Peter Albers. Management of stage I testis cancer. *Eur urol* 2007;51:34-44. *Eur Urol.* 2007 Jul;52(1):295-6. Epub 2007 Feb 14..
- 68) Valdagni R, Salvioni R, **Nicolai N**, Villa S, Bedini N, Bajetta E, Procopio G, Donegani S, Bosisio M. In regard to Kagan: "The multidisciplinary clinic" (*Int J Radiat Oncol Biol Phys* 2005;61:967-968). *Int J Radiat Oncol Biol Phys.* 2005 Sep 1;63(1):309-10.
- 69) Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, **Nicolai N**, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C; European Germ Cell Cancer Consensus Group. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). *Ann Oncol.* 2004 Sep;15(9):1377-99.
- 70) **Nicolai N**. Laparoscopic adrenalectomy. *Tumori.* 2003 Sep-Oct;89(5):556-9.
- 71) **Nicolai N**, Miceli R, Artusi R, Piva L, Pizzocaro G, Salvioni R. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. *J Urol.* 2004 Jan;171(1):172-6.
- 72) Terenziani M, Piva L, Spreafico F, Salvioni R, Massimino M, Luksch R, Cefalo G, Casanova M, Ferrari A, Polastri D, Mazza E, Bellani FF, **Nicolai N**. Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases. *J Pediatr Hematol Oncol.* 2002 Aug-Sep;24(6):454-8.

- 73) Rippa A, Sangalli C, **Nicolai N**, Arena D, Tzoumas S, Franch L. Improvement of endoscopic resection procedures in relation to the volume of prostatic adenoma. *Chir Ital*. 1998;50(1):25-31.
- 74) Pizzocaro G, Piva L, **Nicolai N**. Treatment of lymphatic metastasis of squamous cell carcinoma of the penis: experience at the National Tumor Institute of Milan. *Arch Ital Urol Androl*. 1996 Jun;68(3):169-72.
- 75) Piva L, **Nicolai N**, Di Palo A, Milani A, Merson M, Salvioni R, Stagni S, Vecchio D, Zaroni F, Ferri S, Pizzocaro G. Therapeutic alternatives in the treatment of class T1N0 squamous cell carcinoma of the penis: indications and limitations. *Arch Ital Urol Androl*. 1996 Jun;68(3):157-61.
- 76) **Nicolai N**, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. *J Urol*. 1995 Sep;154(3):1045-9.
- 77) Pizzocaro G, Salvioni R, **Nicolai N**. The role of adjuvant treatment in low-stage germ cell testicular tumors. *Eur Urol*. 1995;28(4):267-72.
- 78) Pizzocaro G, **Nicolai N**, Salvioni R. Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis. *World J Urol*. 1994;12(3):113-9.
- 79) Pizzocaro G, Piva L, Faustini M, Mangiarotti B, **Nicolai N**, Salvioni R, Milani A, Zaroni F. Interferon and vinblastine in presumably operable metastases of renal carcinoma. *rch Ital Urol Androl*. 1993 Apr;65(2):177-80.
- 80) Pizzocaro G, Piva L, Faustini M, **Nicolai N**, Salvioni R, Pisani E, Maggioni A, Mandressi A, Dormia E, Minervini S, et al Adjuvant interferon alpha in renal carcinoma with a high risk of recurrence. Multicenter pilot study. *rch Ital Urol Androl*. 1993 Apr;65(2):173-6.
- 81) **Nicolai N**, Mangiarotti B, Salvioni R, Piva L, Faustini M, Pizzocaro G. Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. *ur Urol*. 1993;23(4):450-6.
- 82) Pizzocaro G, **Nicolai N**, Salvioni R, Piva L, Faustini M, Zaroni F, Milani A. Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors. *Urol*. 1992 Jul;148(1):76-9.
- 83) Zaroni F, Piva L, Milani A, Salvioni R, Faustini M, **Nicolai N**, Mangiarotti B, Pizzocaro G. Chemotherapy of urologic metastases. *rch Ital Urol Nefrol Androl*. 1992 Mar;64(1):37-43.
- 84) Pizzocaro G, Salvioni R, Piva L, Faustini M, **Nicolai N**, Gianni L Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. *Ann Oncol*. 1992 Mar;3(3):211-6.